Midterm patency rate after saphenous vein grafting with a PAS-Port device  by Kai, Masashi et al.
Midterm patency rate after saphenous vein grafting with a
PAS-Port device
Masashi Kai, MD, Michiya Hanyu, MD, Yoshiharu Soga, MD, Takuya Nomoto, MD, Jota Nakano, MD, Takehiko Matsuo, MD,
Masahide Kawato, MD, and Hitoshi Okabayashi, MD, Fukuoka, Japan
BRIEF COMMUNICATIONS: TECHNICALRecently, a new proximal anastomosis device of a saphenous
vein graft (SVG) to the aorta, the PAS-Port device (Cardica,
Redwood City, Calif) has been introduced and yielded en-
couraging results in terms of neurologic complications and
early patency.1,2 However, there is a concern about the mid-
term (at least 1 year after surgical intervention) patency rate.
The aim of this study was to evaluate the midterm patency
rate of SVGs whose proximal anastomosis was performed
with the PAS-Port device.
CLINICAL SUMMARY
Between January 2004 and September 2006, 69 PAS-Port
devices had been used in 66 patients undergoing SVG prox-
imal anastomosis in coronary artery bypass grafting
(CABG) at Kokura Memorial Hospital. Sixty-three patients
had off-pump grafting, and 3 patients had on-pump beating-
heart grafting. The details of the operative data are summa-
rized in Table 1. Bilateral internal thoracic artery grafting for
the left coronary territory was our standard method. The
gastroepiploic artery was our first choice for revasculariza-
tion of the right coronary artery territory. We used SVGs
when (1) stenosis of the native coronary artery was mild
(<90%), (2) arterial conduits had already been used in pre-
vious operations, (3) emergency operations were necessary,
and (4) the patient had a prior history of gastrointestinal
disorders. The proximal anastomosis devices were used
basically in case the ascending aorta showed atheromatous
changes on an epiaortic echocardiogram. Additional 4-
0 Prolene purse-string stitching around the deployed device
was performed in 15 (21.7%) of 69 devices to control the
bleeding. No patients had difficulty achieving the hemosta-
sis. All the operations were performed by one experienced
surgeon. Every patient was given a subcutaneous heparin in-
jection on postoperative days 1 to 4 to prevent postoperative
stroke and perioperative myocardial infarction. Oral aspirin
was started on postoperative day 1 and continued throughout
the follow-up period. No 30-day mortality or intraoperative
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the operation. Among them, 2 deaths were due to cardiac
causes: congestive heart failure (n ¼ 1) and sudden death
(n ¼ 1). The other 4 deaths were due to noncardiac reasons:
cancer (n ¼ 2), sepsis (n ¼ 1), and liver failure (n ¼ 1). Of
46 midterm survivors (at least 1 year after surgical interven-
tion), 38 (82.6%) consented to late follow-up graft evalua-
tion by means of 3-dimensional computed tomography.
Two of 39 devices were occluded, and the 1-year patency
rate (FitzGibbon grade A) was 94.9%. No obvious stenosis
TABLE 1. Operative data (n ¼ 66)
Age (y), mean  SD 69.7  10.3
Female sex, n (%) 16 (24.2%)
Comorbidity, n (%)
Hypertension 42 (63.6)
Hyperlipidemia 34 (51.5)
Diabetes 25 (37.9)
Peripheral vascular disease 9 (13.6)
Dialysis 14 (21.2)
Cerebrovascular disease 8 (12.1)
Previous coronary intervention 25 (37.9)
Previous myocardial infarction 23 (34.8)
Unstable angina 17 (25.8)
Ejection fraction<40% 6 (9.1)
Left main trunk disease 24 (36.4)
Three-vessel disease 47 (71.2)
Emergency procedure 10 (15.1)
Redo procedure 4 (6.1)
Preoperative IABP 4 (6.1)
BITA grafting 41 (62.1)
Off-pump 63 (95.6)
No. of distal anastomoses, mean  SD 3.7  1.2
Details of saphenous vein grafting, n (%)
Endoscopic harvesting 12 (17.4)
Sequential grafting 26 (37.7)
Target coronary artery, n (%)
Left anterior descending artery 8 (11.6)
Circumflex artery 11 (15.9)
Right coronary artery 43 (62.3)
Right coronary artery and circumflex artery 7 (10.1)
Degree of stenosis, n (%)
90%< 34 (49.3)
75%> 35 (50.7)
Location of the proximal anastomosis, n (%)
Ascending aorta 68 (98.6)
Descending aorta 1 (1.4)
SD, Standard deviation; IABP, intra-aortic balloon pump; BITA, bilateral internal tho-
racic artery.ardiovascular Surgery c Volume 137, Number 2 503
Brief CommunicationsTABLE 2. Details of the occluded saphenous vein grafts
Preoperative
characteristics
Endoscopic
harvesting
Sequential
grafting
Target
coronary artery
Degree of
stenosis
Location of the
proximal anastomosis
73-year-old man Diabetes No No RCA 75% Ascending aorta
49-year-old man Dialysis, diabetes, CVD No No RCA 90% Ascending aorta
RCA, Right coronary artery; CVD, cerebrovascular disease.of SVGs (FitzGibbon grade B) was observed. Of the 38 pa-
tients who underwent late graft evaluation, 24 did so at least
2 years after surgical intervention. The 2-year cumulative
patency rate was 91.7% (22/24). All the results were evalu-
ated by an experienced radiologist. Details of the occluded
SVGs are given in Table 2.
DISCUSSION
Stroke is a devastating complication of CABG.Manipula-
tion of the aorta using techniques such as crossclamping is
thought to be a predisposing risk factor. The off-pump tech-
nique has brought more attention to reduce this devastating
complication. Use of an aortic side clamp requires aortic
manipulation, thereby precluding the major advantage of
the off-pump technique. Several devices for proximal anas-
tomosis of SVGs to the aorta have been developed and can
facilitate clampless proximal anastomosis. Although the re-
sults have been satisfactory in terms of neurologic complica-
tions, there have been some concerns about early and long-
term patency rates. The early patency rate of the previous
generation of the proximal anastomosis device, the Symme-
try device (St Jude Medical, Inc, Minneapolis, Minn), was
satisfactory, but production was discontinued because of
the poor midterm and long-term results.3-5 The PAS-Port de-
vice has the potential to yield better results than the Symme-
try device for the following reasons: (1) the stents were
located outside and not inside the SVG, which did not reduce
the total amount of blood exposed to nonintimal surfaces in-
side the aortic lumen, and (2) the stents were composed ofLate rupture of polytetrafluoroethyle
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can cause intimal hyperplasia.1
We realize that the gold standard for the evaluation of
graft patency is angiography. It is relatively difficult to as-
sess the details of anastomosis sites with computed tomogra-
phy. Therefore we might have missed a number of stenotic
vessels. In addition, this is a very small cohort of patients.
In conclusion, this study demonstrated the satisfactory
results of midterm patency rate after placement of SVGs
with a PAS-Port device. This device could be useful for
CABG in case the ascending aorta showed the severe ather-
omatous change to a degree that precluded the use of a side
clamp. However, a larger-scale study and a longer follow-
up period will be mandatory to confirm the reliability of
this device.
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Mitral valve repair is the procedure of choice to correct mitral
regurgitation. The introduction of polytetrafluoroethylene
(PTFE) sutures was an important contribution by David1
and Zussa and colleagues2 for the treatment of chordal short-
ening or for chordal replacement during mitral valve repair.
This report describes a patient with acute-onset hematuria 11
years aftermitral valve repair whowas found to have fractured
PTFE neochordae necessitating mitral valve replacement.
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